Zealand details Phase 1 obesity data for amylin drug as it plans next steps

SAN ANTONIO — Zealand Pharma, hoping to create the next "foundational" therapy for obesity, detailed more Phase 1 data on its amylin analog that was the backbone of a $1 billion raise this summer. Researchers said ...